MarketInOut Stock Screener Log In | Sign Up

Lakefront Biotherapeutics

AMS • Healthcare • Biotechnology • Quote as of 10/27/2026 17:38
Lakefront Biotherapeutics stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeAMS
Market Capitalization1,731.41 mln
Float44.38 mln
Earnings Date11/12/2026

EPS

9.02
Strong

P / E

3.13
Deeply undervalued

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

1.04
Highly suspicious

1-Year Forecast

31.46
Modest upside

Relative Strength

97 / 100
Top performer

Business Description

Lakefront Biotherapeutics NV is a Belgian biotech company founded in 1999 and headquartered in Mechelen, focused on developing new treatments for cancer and immune system diseases across the US and Europe. The company is advancing several drug candidates through clinical trials, including therapies for conditions such as lupus, lymphoma, and multiple myeloma, with two of its cancer treatments produced directly at the point of patient care. Lakefront works in partnership with Gilead Sciences and was previously known as Galapagos NV before changing its name in May 2026.

Key Fundamentals

EPS9.02
P/E3.13
ROE20.10
RPS15.03
ROIC92.58
ROA17.09
Interest Cover309
EBITDA, mln580
EV / EBITDA-0.70
EV / EBIT-0.70
Revenue, mln991

Quote Details

Last 28.22
Change 0 (0%)
Open 28.12
Volume 96,382
Turnover 2,719,900
Average Volume 75,840

Financial Ratios

Pre-Tax Profit Margin58
Leverage Ratio1.04
Current Ratio32.83
Price / Book0.53
Price / Tangible Book0.69
Debt / Equity0.00
Price / Sales1.76

Financial Strength

Altman Z-Score13.48
Piotroski F-Score 6 / 9
Beneish M-Score1.04
Price to Graham Number0.27
1-Year Target Price31.46

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.83% 95 / 100   
1 Month 8.62% 95 / 100   
2 Months 13.88% 92 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog